- Home
- QTTB vs OESX Comparison
QTTB vs OESX Comparison
Compare QTTB & OESX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- OESX
- Stock Information
- Founded
- QTTB 2015
- OESX 1996
- Country
- QTTB United States
- OESX United States
- Employees
- QTTB N/A
- OESX N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- OESX Building Products
- Sector
- QTTB Health Care
- OESX Consumer Discretionary
- Exchange
- QTTB Nasdaq
- OESX Nasdaq
- Market Cap
- QTTB 27.7M
- OESX 26.7M
- IPO Year
- QTTB N/A
- OESX 2007
- Fundamental
- Price
- QTTB $1.86
- OESX $0.75
- Analyst Decision
- QTTB Hold
- OESX Strong Buy
- Analyst Count
- QTTB 8
- OESX 1
- Target Price
- QTTB $24.00
- OESX $3.00
- AVG Volume (30 Days)
- QTTB 242.9K
- OESX 77.9K
- Earning Date
- QTTB 03-11-2025
- OESX 02-11-2025
- Dividend Yield
- QTTB N/A
- OESX N/A
- EPS Growth
- QTTB N/A
- OESX N/A
- EPS
- QTTB N/A
- OESX N/A
- Revenue
- QTTB N/A
- OESX $85,262,000.00
- Revenue This Year
- QTTB N/A
- OESX N/A
- Revenue Next Year
- QTTB N/A
- OESX $17.14
- P/E Ratio
- QTTB N/A
- OESX N/A
- Revenue Growth
- QTTB N/A
- OESX N/A
- 52 Week Low
- QTTB $1.85
- OESX $0.68
- 52 Week High
- QTTB $53.79
- OESX $1.53
- Technical
- Relative Strength Index (RSI)
- QTTB 23.73
- OESX 34.88
- Support Level
- QTTB $2.04
- OESX $0.74
- Resistance Level
- QTTB $2.43
- OESX $0.82
- Average True Range (ATR)
- QTTB 0.20
- OESX 0.06
- MACD
- QTTB 0.11
- OESX -0.01
- Stochastic Oscillator
- QTTB 1.82
- OESX 4.39
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About OESX Orion Energy Systems Inc.
Orion Energy Systems Inc is a developer, manufacturer, and seller of lighting and energy management systems. The company segments include Orion Lighting Segment, Orion Maintenance Segment and Orion Electric Vehicle Charging Segment. It derives maximum revenue from Lighting Segment.